MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies - Says Chief Executive Officer Maher Masoud acquired 100,000 shares in the company between Friday and Monday. Masoud purchased the shares at an average of 489.07 US cents each in New York on the open market. These comprise his entire shareholding so far in MaxCyte, giving him an approximate 0.1% stake. Masoud, who became CEO in January, also holds a further 1.1 million options over MaxCyte's common stock and 400,000 performance stock units.

Current stock price: 390.00 pence, up 4.0% in London on Tuesday morning

12-month change: up 5.4%

By Emma Curzon, Alliance News reporter

Comments and questions to

Copyright 2024 Alliance News Ltd. All Rights Reserved.